SYGNIS AG Announces Completion of Relocation of its Innova Biosciences Unit
News Oct 18, 2017
SYGNIS AG has announced the completion of the relocation of its subsidiary company, Innova Biosciences, into the Company’s existing facilities in Cambridge, UK.
The relocation follows the recent acquisition of Innova Biosciences by SYGNIS AG, and the continued integration of Innova within the SYGNIS Group of companies. This change completes the relocation of Innova’s R&D, manufacturing and logistics departments. To enable the relocation, the Company has invested in the development of 3,000 sqft of new laboratory space at its Cambridge facility. This has doubled the Group’s R&D capabilities in Cambridge and also provides the necessary space and resource required to meet the increasing demand for the Company’s services offering, as well as allow for expansion of its kit manufacturing capabilities.
The R&D facility at Cambridge will predominantly focus on proteomics product and technology development whilst genomics R&D will continue to be based at the Group’s facility in Madrid, Spain. Whilst the R&D effort is located in core centres of excellence in different geographic locations, the groups are interacting closely together on the Group’s core projects in the fields of liquid biopsy and lateral flow assay technology in development with several new joint projects feeding into product development pipeline.
Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, commented: “We have seen rapid growth in demand for the innovative products and services across the entire spectrum of the Company’s offering ranging across the fields of genomics, proteomics and immunology. Amongst the drivers of this demand are Innova`s easy-to-use, cutting-edge bioconjugation technologies and services. With the combination of our sites in Cambridge, the acquisition and relocation of Innova into the SYGNIS Group has been completed. The relocation and site expansion sets the Group up well to continue along its strong growth path to continue to delivering new innovative and high added value products and services for our customers.”
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.